Aducanumab: A Deep Dive into BIIB037 and its Impact A medication, originally known as BIIB037, constitutes a notable effort to address early-stage Alzheimer's disease. Designed by Biogen, aducanumab works by targeting https://www.targetmol.com/compound/aducanumab